Todays Report: Today, Teva Pharmaceutical Industries Ltd. (TEVA) Position Boosted by Cornerstone Investment Partners LLC

Today, Teva Pharmaceutical Industries Ltd. (TEVA) Position Boosted by Cornerstone Investment Partners LLC

Cornerstone Investment Partners LLC increased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,481 shares of the company’s stock after buying an additional 52 shares during the period. Cornerstone Investment Partners LLC’s holdings in Teva Pharmaceutical Industries were worth $1,632,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Krilogy Financial LLC increased its position in Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock valued at $132,000 after buying an additional 25 shares during the last quarter. Veritable L.P. increased its position in Teva Pharmaceutical Industries by 0.5% in the second quarter. Veritable L.P. now owns 5,216 shares of the company’s stock valued at $262,000 after buying an additional 26 shares during the last quarter. Toronto Dominion Bank increased its position in Teva Pharmaceutical Industries by 0.6% in the second quarter. Toronto Dominion Bank now owns 6,025 shares of the company’s stock valued at $304,000 after buying an additional 35 shares during the last quarter. Trust Co increased its position in Teva Pharmaceutical Industries by 0.3% in the first quarter. Trust Co now owns 13,980 shares of the company’s stock valued at $748,000 after buying an additional 40 shares during the last quarter. Finally, WESPAC Advisors SoCal LLC increased its position in Teva Pharmaceutical Industries by 1.4% in the second quarter. WESPAC Advisors SoCal LLC now owns 3,550 shares of the company’s stock valued at $178,000 after buying an additional 50 shares during the last quarter. 60.53% of the stock is currently owned by institutional investors and hedge funds.

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) traded down 0.16% during trading on Monday, reaching $38.15. 4,883,086 shares of the company’s stock were exchanged. Teva Pharmaceutical Industries Ltd. has a 52-week low of $37.12 and a 52-week high of $66.55. The stock has a market cap of $38.72 billion, a PE ratio of 22.19 and a beta of 0.73. The stock’s 50 day moving average price is $41.37 and its 200-day moving average price is $49.12.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.29 by $0.02. Teva Pharmaceutical Industries had a net margin of 8.81% and a return on equity of 16.75%. The company earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. During the same quarter in the prior year, the firm posted $1.35 EPS. The firm’s quarterly revenue was up 15.3% on a year-over-year basis. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post $5.14 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date of this dividend is Thursday, December 1st. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is presently 50.58%.

A number of equities research analysts have issued reports on TEVA shares. Mizuho restated a “buy” rating and set a $64.00 price target (down from $70.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, August 25th. Jefferies Group restated a “buy” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 3rd. Guggenheim restated a “buy” rating and set a $80.00 price target on shares of Teva Pharmaceutical Industries in a report on Monday, August 15th. Morgan Stanley set a $63.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, September 12th. Finally, RBC Capital Markets set a $71.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Sunday, September 11th. Twelve analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $59.80.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

Related posts

Leave a Comment